Explore the Global Chronic Granulomatous Disease (CGD) Management Market — Key Trends, Regional Growth, Top Players, and 10-Year Forecast from 2026 to 2036

Future Market Insights

Chronic Granulomatous Disease (CGD) Management Market

Key Insight

Chronic granulomatous disease (CGD) management sales will strengthen through 2036, anchored by x-linked chronic granulomatous disease at 68.5% of the category segment in 2026. The market was valued at USD 1.44 billion in 2025 and is expected to be worth USD 2.34 billion by 2036, creating an incremental opportunity of USD 0.83 billion.

April 28, 2026

Anurag Sharma

299 Pages

Cite this Report

Chronic Granulomatous Disease (CGD) Management Market

https://www.futuremarketinsights.com/reports/chronic-granulomatous-disease-management-market

License

Buy Now

Summary ToC Companies

Key Players

Avrobio Inc
Editas Medicine
Genethon
Horizon Therapeutics
Mustang Bio
Novartis
Orchard Therapeutics
Regeneron Pharmaceuticals
Rocket Pharmaceuticals
Sangamo Therapeutics
Takeda Pharmaceutical Company Limited

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Chronic Granulomatous Disease (CGD) Management Market

Key Players

Similar Industry Reports